Catheter Precision, Inc. Announces The Presentation Of The First Clinical Data On LockeT
Portfolio Pulse from Benzinga Newsdesk
Catheter Precision, Inc. (NYSE:VTAK), a US-based medical device company, announced the presentation of the first clinical data on LockeT at the Western Atrial Fibrillation Symposium. The study shows LockeT is safe, effective, and offers cost savings and same-day hospital discharge benefits. LockeT is a suture retention device for hemostasis after venous punctures, registered with the FDA.
February 22, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catheter Precision, Inc. announces the presentation of the first clinical data on LockeT, demonstrating its safety, efficacy, and additional benefits, at the Western Atrial Fibrillation Symposium.
The presentation of positive clinical data on LockeT at a prestigious symposium could significantly boost investor confidence in Catheter Precision, Inc. The demonstrated safety, efficacy, and additional benefits such as cost savings and same-day hospital discharge could lead to increased adoption of LockeT, potentially driving up revenues and positively impacting VTAK's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90